Literature DB >> 27186404

Transient fasting enhances replication of oncolytic herpes simplex virus in glioblastoma.

Shinichi Esaki1, Samuel D Rabkin2, Robert L Martuza2, Hiroaki Wakimoto2.   

Abstract

Short-term nutritional restriction (fasting) has been shown to enhance the efficacy of chemotherapy by sensitizing cancer cells and protecting normal cells in a variety of cancer models, including glioblastoma (GBM). Cancer cells, unlike normal cells, respond to fasting by promoting oncogenic signaling and protein synthesis. We hypothesized that fasting would increase the replication of oncolytic herpes simplex virus (oHSV) in GBM. Patient-derived GBM cell lines were fasted by growth in glucose and fetal calf serum restricted culture medium. "Transient fasting", 24-hour fasting followed by 24-hour recovery in complete medium, increased late virus gene expression and G47Δ yields about 2-fold in GBM cells, but not in human astrocytes, and enhanced G47Δ killing of GBM cells. Mechanistically, "transient fasting" suppressed phosphorylation of the subunit of eukaryotic initiation factor 2α (eIF2α) and c-Jun N-terminal kinases (JNK) in GBM cells, but not in astrocytes. Pharmacological inhibition of JNK also increased G47Δ yield. In vivo, transient fasting (48-hour food restriction and 24-hour recovery) doubled luciferase activity after intratumoral G47Δ-US11fluc injection into orthotopic GBM xenografts. Thus, "transient fasting" increases G47Δ replication and oncolytic activity in human GBM cells. These results suggest that "transient fasting" may be effectively combined to enhance oncolytic HSV therapy of GBM.

Entities:  

Keywords:  JNK; Oncolytic HSV; eIF2α; fasting; glioblastoma; mTOR

Year:  2016        PMID: 27186404      PMCID: PMC4859661     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  34 in total

Review 1.  Active immunotherapy: oncolytic virus therapy using HSV-1.

Authors:  Tomoki Todo
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

Review 2.  Starvation, detoxification, and multidrug resistance in cancer therapy.

Authors:  Changhan Lee; Lizzia Raffaghello; Valter D Longo
Journal:  Drug Resist Updat       Date:  2012-03-04       Impact factor: 18.500

3.  Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial.

Authors:  J M Markert; M D Medlock; S D Rabkin; G Y Gillespie; T Todo; W D Hunter; C A Palmer; F Feigenbaum; C Tornatore; F Tufaro; R L Martuza
Journal:  Gene Ther       Date:  2000-05       Impact factor: 5.250

4.  Inhibition of PKR activation by the proline-rich RNA binding domain of the herpes simplex virus type 1 Us11 protein.

Authors:  J Poppers; M Mulvey; D Khoo; I Mohr
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

5.  The Jun kinase 2 isoform is preferentially required for epidermal growth factor-induced transformation of human A549 lung carcinoma cells.

Authors:  F Bost; R McKay; M Bost; O Potapova; N M Dean; D Mercola
Journal:  Mol Cell Biol       Date:  1999-03       Impact factor: 4.272

6.  Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors.

Authors:  Hiroaki Wakimoto; Santosh Kesari; Christopher J Farrell; William T Curry; Cecile Zaupa; Manish Aghi; Toshihiko Kuroda; Anat Stemmer-Rachamimov; Khalid Shah; Ta-Chiang Liu; Deva S Jeyaretna; Jason Debasitis; Jan Pruszak; Robert L Martuza; Samuel D Rabkin
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

7.  Oncolytic herpes simplex virus counteracts the hypoxia-induced modulation of glioblastoma stem-like cells.

Authors:  Donatella Sgubin; Hiroaki Wakimoto; Ryuichi Kanai; Samuel D Rabkin; Robert L Martuza
Journal:  Stem Cells Transl Med       Date:  2012-03-21       Impact factor: 6.940

Review 8.  Oncolytic virotherapy.

Authors:  Stephen J Russell; Kah-Whye Peng; John C Bell
Journal:  Nat Biotechnol       Date:  2012-07-10       Impact factor: 54.908

Review 9.  mTOR Signaling in Protein Translation Regulation: Implications in Cancer Genesis and Therapeutic Interventions.

Authors:  Mehvish Showkat; Mushtaq A Beigh; Khurshid I Andrabi
Journal:  Mol Biol Int       Date:  2014-11-20

10.  Fasting enhances the response of glioma to chemo- and radiotherapy.

Authors:  Fernando Safdie; Sebastian Brandhorst; Min Wei; Weijun Wang; Changhan Lee; Saewon Hwang; Peter S Conti; Thomas C Chen; Valter D Longo
Journal:  PLoS One       Date:  2012-09-11       Impact factor: 3.240

View more
  8 in total

1.  Blockade of transforming growth factor-β signaling enhances oncolytic herpes simplex virus efficacy in patient-derived recurrent glioblastoma models.

Authors:  Shinichi Esaki; Fares Nigim; Esther Moon; Samantha Luk; Juri Kiyokawa; William Curry; Daniel P Cahill; Andrew S Chi; A John Iafrate; Robert L Martuza; Samuel D Rabkin; Hiroaki Wakimoto
Journal:  Int J Cancer       Date:  2017-08-26       Impact factor: 7.396

Review 2.  Teserpaturev/G47Δ: First Approval.

Authors:  James E Frampton
Journal:  BioDrugs       Date:  2022-09       Impact factor: 7.744

Review 3.  Enhanced Therapeutic Efficacy in Cancer Patients by Short-term Fasting: The Autophagy Connection.

Authors:  Gustav van Niekerk; Suzèl M Hattingh; Anna-Mart Engelbrecht
Journal:  Front Oncol       Date:  2016-11-14       Impact factor: 6.244

Review 4.  New frontiers in oncolytic viruses: optimizing and selecting for virus strains with improved efficacy.

Authors:  Kenneth Lundstrom
Journal:  Biologics       Date:  2018-02-09

5.  Active-site mTOR inhibitors augment HSV1-dICP0 infection in cancer cells via dysregulated eIF4E/4E-BP axis.

Authors:  Chadi Zakaria; Polen Sean; Huy-Dung Hoang; Louis-Phillipe Leroux; Margaret Watson; Samuel Tekeste Workenhe; Jaclyn Hearnden; Dana Pearl; Vinh Tai Truong; Nathaniel Robichaud; Akiko Yanagiya; Soroush Tahmasebi; Seyed Mehdi Jafarnejad; Jian-Jun Jia; Adrian Pelin; Jean-Simon Diallo; Fabrice Le Boeuf; John Cameron Bell; Karen Louise Mossman; Tyson Ernst Graber; Maritza Jaramillo; Nahum Sonenberg; Tommy Alain
Journal:  PLoS Pathog       Date:  2018-08-23       Impact factor: 6.823

6.  Starvation-Induced Differential Virotherapy Using an Oncolytic Measles Vaccine Virus.

Authors:  Gabriel Scheubeck; Susanne Berchtold; Irina Smirnow; Andrea Schenk; Julia Beil; Ulrich M Lauer
Journal:  Viruses       Date:  2019-07-05       Impact factor: 5.048

Review 7.  Viral Vector-Based Melanoma Gene Therapy.

Authors:  Altijana Hromic-Jahjefendic; Kenneth Lundstrom
Journal:  Biomedicines       Date:  2020-03-16

Review 8.  Metabolic Reprogramming by Reduced Calorie Intake or Pharmacological Caloric Restriction Mimetics for Improved Cancer Immunotherapy.

Authors:  Erwan Eriau; Juliette Paillet; Guido Kroemer; Jonathan G Pol
Journal:  Cancers (Basel)       Date:  2021-03-12       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.